NEWSLETTER
RSS
MOBILE
HELP
Medarex, Inc. (MEDX)
SHARE
Email Confirmation
OPEN
LAST
$
PREV CLOSE
CHANGE
VOLUME
Overview
News
People
Financials
Company Information
Howard H. Pien, Director/CEO/President/Chairman of the Board
707 State Road
Princeton, NJ 08540
US
Map it 
Overview
A biopharmaceutical company, focuses on the discovery, development and commercialization of human antibody-based therapeutic product candidates.
Press Releases
-
PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008 Sep-18-2008, 11:20AM EDT
-
Medarex to Present at the UBS Global Life Sciences Conference Sep-17-2008, 04:00PM EDT
News From Around the Web
News
-
Sep 15 2008
Employees
Number of Employees: 500
Revenue per Employee: $95,705
Top Executives
Dr. Nils Lonberg, Ph.D., Senior VP/Other Corporate Officer
Irwin Lerner, Other Corporate Officer
Ursula B. Bartels, J.D., Senior VP/General Counsel/Secretary
Christian S. Schade, CFO/Senior VP, Divisional
Dr. Geoffrey M. Nichol, M.B.Ch.B., Divisional Senior VP
Dr. Ronald A. Pepin, Ph.D., Divisional Senior VP
W. Bradford Middlekauff, J.D., Senior VP, Divisional
Board of Directors
Dr. Patricia M. Danzon, Ph.D., Director
Irwin Lerner, Other Corporate Officer
Ursula B. Bartels, J.D., Senior VP/General Counsel/Secretary
Abhijeet J. Lele, Director
Dr.Julius Vida, Ph.D., M.B.A., Director
Dr. Ronald J. Saldarini, Ph.D., Director
Financials
Quarterly
Annual
| Income Statement | 08/2008 | 05/2008 | 02/2008 | 11/2007 |
|---|---|---|---|---|
| Sales | -3.74 Mil. | -3.42 Mil. | -4.57 Mil. | -3.11 Mil. |
| Gross Operating Profit | 13.7 Mil. | 15.42 Mil. | 25.07 Mil. | 15.53 Mil. |
| Operating Income before D & A (EBITDA) | -51.31 Mil. | -46.28 Mil. | -43.69 Mil. | -46.78 Mil. |
| Total Income Before Interest Expenses (EBIT) | -51.55 Mil. | 104.88 Mil. | -43.44 Mil. | -51.61 Mil. |
| Total Net Income | -53.1 Mil. | 103.31 Mil. | -44.82 Mil. | -51.56 Mil. |
| Basic EPS, Total | -0.42 | 0.81 | -0.35 | -0.41 |
| Diluted EPS, Total | -0.42 | 0.76 | -0.35 | -0.41 |
| BALANCE STATEMENT | 08/2008 | 05/2008 | 02/2008 | 11/2007 |
|---|---|---|---|---|
| Cash and Equivalents | 129.01 Mil. | 153.3 Mil. | 37.34 Mil. | 33.72 Mil. |
| Total Assets | 445.22 Mil. | 480.3 Mil. | 529.78 Mil. | 417.86 Mil. |
| Total Liabilities | 71.43 Mil. | 64.32 Mil. | 81.64 Mil. | 81.51 Mil. |
| Total Capitalization | 468.66 Mil. | 540.29 Mil. | 588.76 Mil. | 633.43 Mil. |
| Cash Flow | 08/2008 | 05/2008 | 02/2008 | 11/2007 |
|---|---|---|---|---|
| Net Cash From Continuing Operations | -85.4 Mil. | -45.37 Mil. | -148.57 Mil. | -106.45 Mil. |
| Net Cash From Investing Activities | 170.34 Mil. | 156.73 Mil. | 134.46 Mil. | 91.16 Mil. |
| Net Cash From Financing Activities | 3.17 Mil. | 1.03 Mil. | 16.26 Mil. | 13.16 Mil. |
| Net Change in Cash & Cash Equivalents | 91.67 Mil. | 115.96 Mil. | 2.82 Mil. | -1.3 Mil. |
| Income Statement | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|
| Sales | -15.65 Mil. | -16.69 Mil. | -18.36 Mil. | -20.93 Mil. |
| Gross Operating Profit | 71.91 Mil. | 65.34 Mil. | 69.82 Mil. | 33.41 Mil. |
| Operating Income before D & A (EBITDA) | -173.34 Mil. | -181.1 Mil. | -94.08 Mil. | -112.91 Mil. |
| Total Income Before Interest Expenses (EBIT) | -25.59 Mil. | -183.45 Mil. | -145.82 Mil. | -173.63 Mil. |
| Total Net Income | -27.07 Mil. | -181.7 Mil. | -146 Mil. | -186.51 Mil. |
| Basic EPS, Total | -0.21 | -1.5 | -1.32 | -2.29 |
| Diluted EPS, Total | -0.21 | -1.5 | -1.32 | -2.29 |
| BALANCE STATEMENT | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|
| Cash and Equivalents | 37.34 Mil. | 34.51 Mil. | 90.6 Mil. | 64.84 Mil. |
| Total Assets | 529.78 Mil. | 511.76 Mil. | 382.92 Mil. | 393.52 Mil. |
| Total Liabilities | 81.64 Mil. | 70.44 Mil. | 53.72 Mil. | 52.41 Mil. |
| Total Capitalization | 588.76 Mil. | 781.75 Mil. | 310.71 Mil. | 404.38 Mil. |
| Cash Flow | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|
| Net Cash From Continuing Operations | -148.57 Mil. | -138.34 Mil. | -88.91 Mil. | -5.98 Mil. |
| Net Cash From Investing Activities | 134.46 Mil. | -55.05 Mil. | 84.11 Mil. | -33.79 Mil. |
| Net Cash From Financing Activities | 16.26 Mil. | 134.9 Mil. | 31.05 Mil. | 31.61 Mil. |
| Net Change in Cash & Cash Equivalents | 2.82 Mil. | -56.09 Mil. | 25.76 Mil. | -8.16 Mil. |
Related Companies by Market Cap
Company Name
Price
Change
Market Cap
1.14 Bil.
1.11 Bil.
1.26 Bil.
1.27 Bil.
Company Profile Change Request
The data provided in our company profiles comes from third party information providers.- To request a change please click here
Also in Portfolio.com
Most Read
Most Emailed
Recently Commented
TOP 5
(Daily)
A smart take on the top stories shaping the business world.
Executives & Careers
(Tuesdays)
A weekly guide to the personalities and ideas that are transforming the business world.
Inside Portfolio.com
(Wednesdays)
Our roundup of the week's best from Portfolio.com.
Culture & Lifestyle
(Fridays)
A weekly guide to the best ways to spend your time - and money.
In This Issue
(Monthly)
Be the first to know when the latest issue of Condé Nast Portfolio magazine is online.
RSS Most Read
Mobile